The Research Program
Why Kentucky Matters to Ibogaine Research
In May 2023, Kentucky's then Attorney General and the chair of its Opioid Abatement Advisory Commission proposed directing $42 million of the state's opioid settlement funds into clinical development of ibogaine for opioid use disorder. Months of public hearings followed, putting researchers, cardiologists, veterans, and treatment advocates on the record about the published evidence: the strongest airing the science had ever received in an American policy forum.
The commission stepped back from the proposal in early 2024 under a new Attorney General, citing ibogaine's Schedule I status and the cost of controlled trials. But the debate did not end there: the initiative's architects carried the case to other states, Texas funded a far larger program in 2025-2026, and Kentucky's own legislature returned to the idea in 2026. The Kentucky hearings are why ibogaine policy is now a live question in US statehouses.
MindScape integrates the research literature that drove that debate into protocol design. The GDNF and neuroprotection findings below directly inform our use of ibogaine for stimulant addiction, Parkinson's disease, and TBI cases, where neuroprotective and GDNF-mediated mechanisms have the greatest clinical relevance.
Key Research Findings
What the Science Shows
GDNF Upregulation
Research from Dorit Ron's laboratory at UCSF found that ibogaine produces significant upregulation of glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area, a brain region central to dopaminergic reward circuitry. GDNF promotes the survival and differentiation of dopaminergic neurons and is among the most potent neuroprotective factors identified in addiction research. This is the science Kentucky's commission was asked to weigh.
Clinical Significance
GDNF elevation is thought to be a key mechanism behind ibogaine's durable anti-addictive effects, persisting long after the compound itself has cleared.
Dopaminergic Neuron Protection
Animal-model studies in the published literature show ibogaine-class compounds can protect dopaminergic neurons from stimulant-induced neurotoxicity. This neuroprotective effect, not seen with any approved addiction pharmacotherapy, has significant implications for stimulant addiction treatment and potentially for Parkinson's disease intervention.
Clinical Significance
Dopamine neuron protection represents a fundamentally different mechanism than substitution-based addiction treatment, addressing underlying neurological damage rather than suppressing symptoms.
Sigma-2 Receptor Modulation
Receptor-binding studies have mapped ibogaine's interaction with sigma-2 receptors, a receptor system implicated in cellular stress and neurodegeneration. Sigma-2 modulation may contribute to ibogaine's anti-addictive and antidepressant effects through mechanisms distinct from its serotonin transporter activity.
Clinical Significance
Sigma receptor research opens potential therapeutic applications beyond addiction, including neurodegeneration and mood disorders.
Serotonin Transporter Inhibition
Ibogaine acts as a non-competitive inhibitor of the serotonin transporter (SERT), distinct in mechanism from traditional SSRIs. This inhibition pattern, combined with its effects on NMDA receptors, opioid receptors, and sigma sites, produces a neuromodulatory profile that no existing approved drug replicates.
Clinical Significance
Understanding ibogaine's SERT interaction relative to SSRIs helps explain why it benefits patients for whom standard antidepressants have failed.
NMDA Receptor Antagonism
Ibogaine and its primary metabolite noribogaine exhibit NMDA receptor antagonism, a mechanism shared by ketamine, which has received FDA approval for treatment-resistant depression. The published pharmacology characterizes this activity and its contribution to ibogaine's acute and sustained antidepressant and anti-craving effects.
Clinical Significance
NMDA antagonism contributes to the rapid-onset antidepressant effect observed in patients after ibogaine treatment, paralleling ketamine's mechanism but with a substantially longer duration of action.
Noribogaine's Extended Role
Pharmacokinetic research characterized noribogaine, ibogaine's primary metabolite, as a therapeutically active compound in its own right. Noribogaine has a far longer half-life than ibogaine and a distinct receptor binding profile, and in April 2026 it became the first ibogaine-class compound with an FDA-accepted IND (DemeRx's DMX-1001 for alcohol use disorder).
Clinical Significance
Noribogaine's extended activity explains why ibogaine's anti-craving and antidepressant effects persist for weeks to months after the acute experience has ended.
Research into Practice
How This Research Informs Our Clinical Protocols
The GDNF research directly supports our protocol design for stimulant addiction cases (cocaine, methamphetamine). Where other treatments have no mechanism for addressing stimulant-induced dopamine neuron damage, ibogaine's GDNF upregulation provides a rational basis for neurological repair, not just symptom management.
The characterization of noribogaine's extended half-life and distinct receptor binding profile informed our progressive booster protocol. By sequencing TA after HCl, adding noribogaine-rich extract after the acute ibogaine phase, we extend the therapeutic window precisely where the research predicts the greatest biological leverage.
For Parkinson's patients, the neuroprotective dopaminergic findings underpin our rationale for ibogaine's application beyond addiction, a use case with growing clinical evidence and enthusiastic patient response in our 10-day extended protocol.
Published Research
Selected Publications
Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption
Journal of Neuroscience, 2005
He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D.
Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits
Frontiers in Pharmacology, 2019
Marton S, et al.
The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
Molecules, 2015
Koenig X, Hilber K.
Ibogaine, an Anti-Addictive Drug: Pharmacology and Time to Go Further in Development
Human & Experimental Toxicology, 2008
Maciulaitis R, et al.
Treatment Grounded in the Science
Our clinical protocols evolve as the research does. Speak with our team about how the current evidence base applies to your specific situation.
Schedule a Confidential Consultation